Czym jest e-papieros?

Na początek warto zajrzeć do Wikipedii, a później wrócić do nas. Digicig.pl to przede wszystkim kompendium ogólnej wiedzy o e-paleniu, poradnik i przewodnik dla tych, którzy niedawno rozpoczęli przygodę z e-papierosem, lub dopiero zastanawiają się nad tym.

Wybieramy sprzęt

Zanim kupisz swojego pierwszego e-papierosa, musisz zdawać sobie sprawę z tego, że są to produkty, które dopiero wchodzą na rynek i nie są pozbawione wad. Jeżeli chcesz kupić sprzęt, który będzie działał niezawodnie co najmniej przez rok, to rozczarujemy cię...  Czytaj...

E-papieros a zdrowie

Czy e-palenie jest szkodliwe dla zdrowia i w jakim stopniu? Co wiadomo o skutkach ubocznych? Postaramy się rzetelnie przedstawić obecny stan wiedzy oraz podawać informacje o prowadzonych badaniach naukowych.
Czytaj...

Strona główna

Literatura naukowa

  1. Society for Research on Nicotine and Tobacco, (SRNT) conference, April 2009. Health New Zealand Ltd research presented at Dublin. (źródło: www.healthnz.co.nz, strona konferencji SRNT, SRNT Poster session abstracts)
    1. E-cigarette Safety: Ruyan e-cigarette benchtop tests: www.healthnz.co.nz/DublinEcigBenchtopHandout.pdf, www.healthnz.co.nz/DublinEcigPoster1.ppt, www.healthnz.co.nz/DublinEcigPoster2.ppt
    2. E-cigarette efficacy. Poster 5-50, Effect of an E-cigarette on Cravings and Withdrawal, Acceptability and Nicotine Delivery: Randomised Cross-over Trial. - www.healthnz.co.nz/ecig_effect-2.pdf
  2. Murray Laugesen: Safety Report on the Ruyan® e-cigarette Cartridge and Inhaled Aerosol - 30 October 2008
  3. Committee on Spacecraft Exposure Guidelines, Committee on Toxicology, National Research Council, Spacecraft Water Exposure Guidelines for Selected Contaminants: Volume 3 - Propylene Glycol, National Academies Press, 2008: 165-188.
  4. Wang T., et al.: Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med. 2007 Winter; 20(4): 417-28.
  5. Cheung RT., et al.: Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res. 2006 Nov; 41(4): 337-43.
  6. Paddock Laboratories Inc. Minneapolis: Propylene Glycol - MATERIAL SAFETY DATA SHEET, 20 April 2005.
  7. Jorens PG., et al.: Unusual D-lactic acid acidosis from propylene glycol metabolism in overdose. J Toxicol Clin Toxicol. 2004; 42(2): 163-9.
  8. Center for the Evaluation of Risks to Human Reproduction (CERHR): NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of propylene glycol. Reproductive Toxicology. Vol. 18 (2004). p. 533-579 Abstract, Full text PDF
  9. Yaucher NE., et al.: Propylene glycol-associated renal toxicity from lorazepam infusion. Pharmacotherapy. 2003 Sep; 23(9): 1094-9.
  10. W Sumner: Estimating the health consequences of replacing cigarettes with nicotine inhalers. Tob Control. 2003 June; 12(2): 124-132.
  11. Chicella M., et al.: Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Crit Care Med. 2002 Dec; 30(12): 2752-6.
  12. Heck JD, et al.: Toxicologic evaluation of humectants added to cigarette tobacco: 13-week smoke inhalation study of glycerin and propylene glycol in Fischer 344 rats. Inhal Toxicol. 2002 Nov; 14(11): 1135-52.
  13. Parker MG, et al.: Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med. 2002 Jan; 28(1): 81-4.
  14. Schneider, NG., et al.: The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001; 40 (9): 661-84.
  15. Glover ML, Reed MD.: Propylene glycol: the safe diluent that continues to cause harm. Pharmacotherapy. 1996 Jul-Aug; 16(4): 690-3.
  16. Molander, L., et al.: Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler. Clin Pharmacol Ther. 1996 Apr; 59 (4): 394-400.
  17. Saini, M., et al.: Hematological alterations in propylene glycol-dosed female rats are minimal. Veterinary and Human Toxicology. Vol. 38, no. 2 (Apr. 1996). p. 81-85.
  18. Russell MA.: The future of nicotine replacement. - Br J Addict. 1991 May; 86(5): 653-8.
  19. Kinnunen T, Koskela M.: Antibacterial and antifungal properties of propylene glycol, hexylene glycol, and 1,3-butylene glycol in vitro. - Acta Derm Venereol. 1991; 71(2): 148-50.
  20. Suber, R.L., et al: Subchronic nose-only inhalation study of propylene glycol in Sprague-Dawley rats. Food and Chemical Toxicology. Vol. 27, no. 9 (1989). p. 573-583.
  21. Russell MA, Jarvis MJ, Sutherland G, Feyerabend C.: Nicotine replacement in smoking cessation. Absorption of nicotine vapor from smoke-free cigarettes. JAMA. 1987 Jun 19; 257(23): 3262-5.
  22. Kelner, M. J. and Bailey, D. N.: Propylene glycol as a cause of lactic acidosis. J Anal Toxicol. 1985 Jan-Feb; 9(1): 40-2.
  23. Thomas PA, Bhat KS, Kotian KM.: Antibacterial properties of dilute formocresol and eugenol and propylene glycol. Oral Surg Oral Med Oral Pathol. 1980 Feb; 49(2): 166-70.
  24. Robertson, O.H., et al.: Tests for the chronic toxicity of propylene glycol and triethylene glycol on monkeys and rats by vapor inhalation and oral administration. Journal of Pharmacology and Experimental Therapeutics. Vol. 91 (Sept. 1947). p. 52-76.
  25. Puck, T.T., et al.: The bactericidal action of propylene glycol vapor on microorganisms suspended in air: II. The influence of various factors on the activity of the vapor. The Journal of Experimental Medicine. 1943; Vol 78, 387-406.
  26. Robertson, O.H., et al.: The bactericidal action of propylene glycol vapor on microorganisms suspended in air. I. The Journal of Experimental Medicine. 1942; Vol 75, 593-610.
  27. HSE Consulting and Sampling, Inc.: Literature Review for Glycerol and Glycols for Entertainment Services & Technology Association.